Acknowledgement to Referees

Drugs Ther Perspect 38, 112-126 (2022). https://doi.org/10.1007/s40267-022-00897-8 * Szkiladz, A., Hegner, S. Evaluation of three barrier-type closed system transfer devices using the 2015 NIOSH vapor containment performance draft protocol. Drugs Ther Perspect 38, 177-184 (2022). https://doi.org/10.1007/s40267-02200905-x Adis Drug or Device Q&A reviews, which are written by employees of Adis International Ltd./Springer Nature as part of the Adis Drug Review programme, were also very popular, including the following published in 2022: * Heo, YA. Dag Aarsland, UK Heba Abdelkader, Egypt Sola Adeleke, UK Niyaz Ahmad, Saudi Arabia Abolfazl Akbari, Islamic Republic of Iran A.Deniz Akkaya, Turkey Juan Pablo Alderuccio, USA Khalidah Alenzi, Saudi Arabia Eman A. Alghamdi, Saudi Arabia Abdulaziz Alhazmi, Saudi Arabia Zainab Ali, Qatar Abdullah Alismail, USA Yazed S. Alsowaida, USA Mohammad Amraee, Islamic Republic of Iran Kamile Arıkan, Turkey Carol Armour, Australia Kurt Ashack, USA Flora N. Balieva, Norway Kalyani Barve, India Kathleen Bennett, Ireland Uwe Bieri, Switzerland Jacqueline Birks, UK Paul A. Bunn, USA Matthew Burge, Australia Luca Busetto, Italy Flavio Cadegiani, Brazil Michael Camilleri, USA Anthony M. Casapao, USA Maria Cerruto, Italy Shao-Ping Chang, Taiwan, Republic of China Y. Chen, China Ann C. Childress, USA Arrigo F.G. Cicero, Italy Philip Cohen, USA Samuele Cortese, UK Saibal Das, India Mellar Davis, USA Francesca De Felice, Italy Florentina-Silvia F.G. Delli, Greece Dana DiBenedetti, USA Hadi Esmaily, Islamic Republic of Iran Roger Evans, Australia Justin Faden, USA Tom Fahey, Ireland Charlotte Forshay, USA Brian M. Frier, UK Jesús Funuyet-Salas, Spain Silvana Galderisi, Italy Hamza Garashi, UK Pere Gascon, Spain Bilun Gemicioglu, Turkey Niloofar Ghadamyari, Turkey Silvia Giovannini, Italy David Graham, USA Stephen Grill, USA Matthew Grissinger, USA Harm R. Haak, The Netherlands Swapnil Hiremath, Canada Alexis E. Horace, USA Robert H. Howland, USA Perpetua U. Ibekwe, Nigeria Ambrose O. Isah, Nigeria Deidre A. Kelly, UK Zakir Khan, Turkey Asmita Priyadarshini Khatiwada, Nepal Barbara Kiesewetter, Austria Hiroshi Kitoh, Japan Haruki Koike, Japan Dimitra Koumaki, Greece Lincy Lal, USA Megan Lam, Canada Roger D. Lander, USA Carl J. Lavie, USA David Liew, Australia Alisa Likhitsup, USA Fanxiao Liu, China Tauqeer H. Mallhi, Saudi Arabia Jason Margolesky, USA Tommaso Martino, Italy Cristiano Matos, Portugal Daniel Medina Luna, Mexico Tasneem F. Mohammad, USA Klaus Mohnike, Germany Sarah Mousavi, Islamic Republic of Iran Tinashe Mudzviti, Zimbabwe Thomas Müller, Germany Richard Musil, Germany Mariasanta Napolitano, Italy Elisa Navarro, USA Weiyi Ni, USA Joshua Niznik, USA Joanna Nowaczyk, Poland Christophe Orssaud, France Ranakishor Pelluri, India Marco Pozzi, Italy Yash Prashar, India Jennifer Pruskowski, USA Olivier Rascol, France Emily Reeve, Australia Omar Salamanca, Colombia Oliver Scherf-Clavel, Germany Martin Schoen, USA Leticia Shea, USA Shatrunajay Shukla, India Damian Skrypnik, Poland Meredith Smith, USA Anshu Srivastava, India Amit K. Srivastava, India Thomas P. Stern, USA Adam Strzelczyk, Germany Rokeya Sultana, India Rajesh Tampi, USA Karina Top, Canada Jean-Louis Vincent, Belgium Giuseppe Vita, Italy Antonio Vitiello, Italy Sarah E. Vordenberg, USA Thasia G. Woodworth, USA Angela Yen Moore, USA Ichiro Yoshii, Japan Seyede Raheleh Yousefi, Islamic Republic of Iran Ismaeel Yunusa, USA Ge Zhang, Hong Kong, China We are also very grateful to the members of the journal's Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes.

Sotrovimab: First Approval.

Sotrovimab (Xevudy®) is a recombinant human monoclonal antibody targeted against the severe acute respiratory syndrome coronavirus 2. It is being developed by Vir Biotechnology in collaboration with GlaxoSmithKline for the treatment of coronavirus disease 2019 (COVID-19). Sotrovimab received its first emergency use authorization in May 2021 for the treatment of COVID-19 in the USA, with interim, emergency or conditional authorizations subsequently granted in several other countries. In December 2021, sotrovimab received its first full approval in the EU for use in adolescents (aged ≥ 12 years and weighing ≥ 40 kg) and adults with COVID-19 who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19. This article summarizes the milestones in the development of sotrovimab leading to this first approval.

ACKNOWLEDGEMENT TO REFEREES

Moaz Abdelwadoud, USA Usman Abubakar, Malaysia Nagesh Adla, India Ayaz Ahmad, Saudi Arabia Ali Ahmed, Malaysia A. Deniz Akkaya, Turkey Esraa E. Al Jomaa, Jordan Ali Aldibbiat, Kuwait Zainab Ali, Qatar Abdullah Alismail, USA Samaher Al-Janabi, Iraq Karel Allegaert, Belgium Abdullah Alsultan, Saudi Arabia Mohammad Amraee, Islamic Republic of Iran Martin Aringer, Germany Carol Armour, Australia Ali Ekrem Aydin, Turkey Shazli Azmi, UK Muthukumar Balasubramaniam, USA Liese Barbier, Belgium Anthony H. Barnett, UK Julio Bassas-Vila, Spain Massimo Bellini, Italy Andrew Blumenfeld, USA James R. Brasic, USA Tommaso Cai, Italy Leonard Calabrese, USA Stefania Campana, Italy Fabrizio Cantini, Italy Marina Caputo, Italy Patricia Cavaco, Portugal Gian P. Caviglia, Italy Renato Caviglia, UK Ercan Celikkayalar, Finland Sonia Chavez-Alvarez, Mexico Y. Chen, China Tiziana Ciarambino, Italy Juan Correa, USA Fiammetta Cosci, Italy John M. Davis, USA Stefano de Biase, Italy Raouia Dhouibi, Tunisia Kevin J. Downes, USA Brian D. Edwards, UK Asma A. El-Shara, Jordan Dwi Endarti, Indonesia Michel Erlewyn-Lajeunesse, UK Gohar Eslami, Islamic Republic of Iran Jian Gao Fan, China Steven R. Feldman, USA Erin R. Fox, USA Brian Godman, Sweden David Graham, USA Paul Grootendorst, Canada Fernando M. Gruz, Argentina Mara Guerreiro, Portugal Mohadeseh Haji Abdolvahab, Islamic Republic of Iran Marianne Harris, Canada Anna M. Hu, USA Demetris Ioannides, Greece Ambrose O. Isah, Nigeria Sambo G. Ishaku, Nigeria Dmitriy V. Ivashchenko, The Russian Federation Viviane Khalil, Australia Tahir Khan, Pakistan Kranthi Swaroop Koonisetty, USA Chrysovalantis Korfitis, Greece Pim N.J. Langendijk, the Netherlands Rupert Leong, Australia Joel Lexchin, Canada Wen-Shyong Liou, Taiwan Fanxiao Liu, China Giovanni Maconi, Italy Sara Manti, Italy Uday Venkat Mateti, India Cristiano Matos, Spain Nokuzola Mbhele, South Africa Bikash R. Meher, India Pavel Mohr, Czech Republic Rebekah Moles, Australia Rashid Muhammed, India Logan Murry, USA Richard Musil, Germany Theophile Niyonsenga, Australia Anna Nowak-Wegrzyn, USA Christophe Orssaud, France Gregory M. Peterson, Australia Elsy F. Ramia, Lebanon Joseph Reilly, USA Doris Rusic, Croatia Omar Salamanca, Colombia Mohammad T. Salman, India Aleyda Sánchez, Mexico Wilhelm W. Schulte-Mattler, Germany Tim Schutte, the Netherlands Renukha Sellappans, Malaysia Vivian Y. Shi, USA Terence Smeaton, Ireland Betul Sozeri, Turkey Amit K. Srivastava, India Richard R. Stark, Australia Justin Taylor, USA Dixon Thomas, United Arab Emirates Pramote Tragulpiankit, Thailand Paolo Usai-Satta, Italy C. Edson Utazi, UK Cristina Valencia-Sanchez, USA Susan M. Webb, Spain Thasia G. Woodworth, USA Delina Xhafaj, Albania Angela Yen Moore, USA Sarah Yim, USA Ichiro Yoshii, Japan Cihan Yurdaydin, Turkey Ashkan Zandi, Islamic Republic of Iran Xiang Zhang, China We are also very grateful to the members of the journal's Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes. Drugs Ther Perspect 37, 29-34 (2021). https://doi. org/10.1007/s40267-020-00792-0 In terms of other important company initiatives, the Springer Nature 'Sustainable Development Goals (SDG) Programme' is aiming to connect researchers who are tackling the world's toughest challenges with practitioners in policy and business, while the 'Women in Science' initiative aims to help empower more women scientists to achieve scientific excellence. [...]we are delighted to inform you that Springer Nature is now carbon neutral for its direct operations (offices, fleet and flights) and earlier this year signed The Climate Pledge, making a commitment to be Net Zero carbon by 2040.

Voclosporin: First Approval.

Voclosporin (Lupkynis™) is an oral calcineurin inhibitor immunosuppressant that is being developed by Aurinia Pharmaceuticals. In January 2021, based on positive results from the pivotal phases II and III trials, oral voclosporin received its first approval in the USA for use in combination with a background immunosuppressive therapy regimen for adults with active lupus nephritis. Voclosporin is also being explored for the novel coronavirus disease 2019 (COVID-19) in kidney transplant recipients. This article summarizes the milestones in the development of voclosporin leading to this first approval for lupus nephritis.